Stephen Wagner, M.D.,F.A.C.C.

Associate Professor of Medicine
Chief of Cardiology, Robley Rex Veterans Affairs Medical Center
Program Director, Cardiology Fellowship
Director, Nuclear Cardiology Training Program

Dr. Wagner's research interests center on preventive cardiology including lipoproteins and other markers for coronary artery disease risk, the relationship of total body iron stores and oxidized LDL, noninvasive diagnostic testing for coronary artery disease and preoperative assessment of cardiac patients undergoing vascular surgery. He has participated as the principal investigator for the University of Louisville in a large number of national cooperative studies including the landmark VA HDL Interventional Trial (HIT), Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE), the recent JUPITER Trial, and has served as a co-investigator in an American Heart Association sponsored trial (Oxidative Susceptibility of Apo-B Containing Lipoproteins as Markers for Coronary Artery Disease). He is a coinvestigator for the Louisville Healthy Heart Study: Exposure to Environmental Aldehydes and Cardiovascular Disease Risk.

Selected Publications:

• Levinson S, Wagner S.  The relative usefulness of automated apolipoprotein A-1 and high density lipoprotein cholesterol assays as markers for coronary artery disease. Am J Clin Path 1994;101:104-108
• Hobbs GA, Wagner SG, Levinson SS.  Relationships between triglycerides, lipoproteins, glucose and coronary artery disease.  Clinica Chimica Acta 1995;238:59-70
• Stoddard M, Wagner SG, Ikram S, Longaker R, Prince CR.  Effects of Nifedipine and Nitroglycerin on Left Ventricular Systolic Dysfunction and Impaired Diastolic Filling After Exercise-Induced Ischemia in Humans.  JACC, 1996;28:915-23
• Rubins HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, et al.  Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circ 2001;103:2828-33.